IONpath appoints Brad Nelson to its leadership team as Senior Vice President of Marketing and Corporate Strategy
PR84443
MENLO PARK, Calif., June 18, 2020 /PRNewswire=KYODO JBN/ --
IONpath, Inc. the leader in multiplexed spatial tissue imaging and analysis,
today announced the appointment of Brad Nelson to the position of Senior Vice
President of Marketing and Corporate Strategy. Mr. Nelson will lead marketing,
product management and application functions to meet the increasing demand for
translational medicine insights that can only be achieved with Multiplexed Ion
Beam Imaging (MIBI(TM)).
Logo - https://mma.prnewswire.com/media/1088947/IONpath_Logo.jpg
Rapid growth in immuno-oncology and adjacent markets requires approaches that
can sensitively detect and quantify the expression of multiple biomarkers while
preserving spatial information. IONpath is uniquely capable of addressing these
market needs and is positioned for rapid commercial growth both with their
MIBIScope(TM) instrument and their comprehensive Research Services offering.
Mr. Nelson will provide commercial leadership as IONpath meets this increasing
demand from pharma, biotech and academic customers.
"Brad brings a unique combination of broad marketing and corporate development
experience and a deep technical background," Dr. Harris Fienberg, IONpath CEO
said. "Our entire team is excited to have Brad on board to guide our
immuno-oncology strategy and expand our offerings into new markets."
Mr. Nelson has over twenty years of experience in leading rapid growth life
science and medical device organizations. He has a track record of success at
early stage companies bringing new technology and applications to market,
driving rapid growth from product inception to broad scale adoption. Most
recently he served as Vice President of Marketing at Magnolia Medical
Technologies leading the brand and product portfolio development for the
company's Steripath technology which experienced rapid adoption and over 70
percent annual revenue growth.
Prior to Magnolia Medical, Mr. Nelson served as Head of Marketing and Director
of Corporate Development at Labcyte Inc., leading the development of new global
markets and collaborations that delivered sustained revenue growth and the
acquisition by Danaher Corporation. Previously he led the marketing
organization at Velocity11 Inc., building a highly differentiated brand and
robotics product portfolio that led to industry leading growth and the
acquisition by Agilent Technologies.
"I am thrilled to join the world class team at IONpath," Nelson said. "IONpath
has the rare combination of groundbreaking technology backed by a team of
scientists and engineers that can turn data into insights. Working closely with
our pharmaceutical, biotech and academic partners we will deliver on the
promise of precision medicine for oncology, immunology, neuroscience and
infectious disease markets enabling new discoveries that improve patient care."
About IONpath, Inc. and IONpath Research Services
IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery
and improve human health. The company's MIBIscope(TM) System utilizes
Multiplexed Ion Beam Imaging (MIBI(TM)) technology, developed at Stanford
University, and represents a transformative step in tissue imaging by
simultaneously multiplexing up to 40 markers with specificity down to a single
cell. Leading research institutes, biotech and pharmaceutical companies are
using the MIBIscope in immuno-oncology, immunology and neuroscience research
where high-fidelity multiplexed imaging data is needed. In addition to the
MIBIscope(TM) System enhanced with MIBItracker(TM), IONpath empowers the
research and development initiatives of academic, biotech and pharmaceutical
partners through its comprehensive Research Services division.
Visit www.ionpath.com to learn more.
(c)2020 IONpath, Inc. All rights reserved. IONpath(R) is a registered trademark
and MIBI(TM) & MIBIscope(TM) are trademarks of IONpath, Inc. For Research Use
Only. Not for diagnostic use.
SOURCE IONpath, Inc.
CONTACT: Terri Hnatyszyn, media@ionpath.com, (305) 803-0824
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。